JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 44(2010) N 5 p. 776-786;
P.V. Spirin1, D. Baskaran1, N.N. Orlova1, A.V. Rulina1, N.A. Nikitenko1, E.L. Chernolovskaya3, M.A. Zenkova3, V.V. Vlasov3, P.M. Rubtsov1, P.M. Chumakov1, C. Stocking2, V.S. Prasolov1*

Downregulation of Activated Leukemic Oncogenes AML1-ETO and RUNX1(K83N) Expression with RNA-Interferenc

1Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Moscow, 119991, Russia
2Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, 20251, Germany
3Institute of Chemical biology and Fundamental Medicine of Siberian Branch of Russian Academy of Sciences, Novosibirsk, 630090, Russia

*prasolov@eimb.ru
Received - 2010-01-25; Accepted - 2010-04-08

In the present study, we have applied the siRNA approach to reduce the expression of AML1-ETO and RUNX1(K83N) oncogenes, which are frequently found in leukemic cells. We have designed small hairpin RNAs (shRNA) for targeting AML1-ETO oncogene and a region close to the 5'-untranslated region of mRNA for the mutant RUNX1(K83N) oncogene and expressed the shRNAs in lentiviral vectors. We report a stable reduction in expression of oncogenes following the introduction of shRNAs into cells.

regulation of gene expression, posttranscriptional regulation of expression, RNA-interference, acute myeloid leukemia (AML), siRNA, shRNA, lentiviral vectors



JMB-FOOTER RAS-JOURNALS